Cytos gains protein discovery tech patent

13 March 2001

Switzerland's Cytos Biotechnology AG, which discovers and develops newprotein drugs and protein-based immunotherapeutics, has been awarded US Patent No 6,197,502, Expression cloning process for the discovery, characterization and isolation of genes encoding polypeptides with a predetermined property.

Cytos chief executive Wolfgang Renner says that, with this patent, the company has secured broad protection for an essential technology that facilitates drug discovery and differentiates its system from that of competitors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight